Research ExplorerPublicationsRadiotherapy for oligometastatic disease in patients with sp...

Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors.

Standard

Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors. / Freundt, Katja; Meyners, Thekla; Bajrovic, Amira; Basic, Hiba; Karstens, Johann H; Adamietz, Irenaeus A; Rudat, Volker; Schild, Steven E; Dunst, Juergen; Rades, Dirk.

In: STRAHLENTHER ONKOL, Vol. 186, No. 4, 4, 2010, p. 218-223.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Freundt, K, Meyners, T, Bajrovic, A, Basic, H, Karstens, JH, Adamietz, IA, Rudat, V, Schild, SE, Dunst, J & Rades, D 2010, 'Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors.', STRAHLENTHER ONKOL, vol. 186, no. 4, 4, pp. 218-223. <http://www.ncbi.nlm.nih.gov/pubmed/20354660?dopt=Citation>

APA

Freundt, K., Meyners, T., Bajrovic, A., Basic, H., Karstens, J. H., Adamietz, I. A., Rudat, V., Schild, S. E., Dunst, J., & Rades, D. (2010). Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors. STRAHLENTHER ONKOL, 186(4), 218-223. [4]. http://www.ncbi.nlm.nih.gov/pubmed/20354660?dopt=Citation

Vancouver

Freundt K, Meyners T, Bajrovic A, Basic H, Karstens JH, Adamietz IA et al. Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors. STRAHLENTHER ONKOL. 2010;186(4):218-223. 4.

Bibtex

@article{f83846d902d64a46a5cef132e757079a,
title = "Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors.",
abstract = "Radiotherapy alone is the most common treatment for metastatic spinal cord compression (MSCC). Patients with relatively radioresistant tumors and oligometastatic disease may benefit from more intensive therapies (surgery, high-precision radiotherapy). If such therapies are not available, one can speculate whether patients benefit from dose escalation beyond the standard regimen 30 Gy in ten fractions.",
author = "Katja Freundt and Thekla Meyners and Amira Bajrovic and Hiba Basic and Karstens, {Johann H} and Adamietz, {Irenaeus A} and Volker Rudat and Schild, {Steven E} and Juergen Dunst and Dirk Rades",
year = "2010",
language = "Deutsch",
volume = "186",
pages = "218--223",
journal = "STRAHLENTHER ONKOL",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "4",

}

RIS

TY - JOUR

T1 - Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors.

AU - Freundt, Katja

AU - Meyners, Thekla

AU - Bajrovic, Amira

AU - Basic, Hiba

AU - Karstens, Johann H

AU - Adamietz, Irenaeus A

AU - Rudat, Volker

AU - Schild, Steven E

AU - Dunst, Juergen

AU - Rades, Dirk

PY - 2010

Y1 - 2010

N2 - Radiotherapy alone is the most common treatment for metastatic spinal cord compression (MSCC). Patients with relatively radioresistant tumors and oligometastatic disease may benefit from more intensive therapies (surgery, high-precision radiotherapy). If such therapies are not available, one can speculate whether patients benefit from dose escalation beyond the standard regimen 30 Gy in ten fractions.

AB - Radiotherapy alone is the most common treatment for metastatic spinal cord compression (MSCC). Patients with relatively radioresistant tumors and oligometastatic disease may benefit from more intensive therapies (surgery, high-precision radiotherapy). If such therapies are not available, one can speculate whether patients benefit from dose escalation beyond the standard regimen 30 Gy in ten fractions.

M3 - SCORING: Zeitschriftenaufsatz

VL - 186

SP - 218

EP - 223

JO - STRAHLENTHER ONKOL

JF - STRAHLENTHER ONKOL

SN - 0179-7158

IS - 4

M1 - 4

ER -